EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long-term retention rates of anti-tumour necrosis factor and anti-interleukin-17 antibodies for patients with psoriatic arthritis

Kenji Takami iD, Shigeyoshi Tsuji, Sachina Sato, Kazuya Akaji, Chigusa Yamashita, Shiori Hiroumi, Hachiro Konaka, Misa Hayashi, Mari Higashiyama

Modern Rheumatology · 2024

DOI: 10.1093/mr/road111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Kenji Takami und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Nippon Life Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Interleukin-17, Antibodies, Monoclonal, Humanized, Antirheumatic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

While biologics have been used for the patients with psoriatic arthritis, there remains to be unknown concerning long-term retention rates. This study aims to present real-world data about long-term retention rates of biologics for the patients with psoriatic arthritis, and to undertake an analysis of the contributing factors.

Methods

We examined retention rates and the reasons for discontinuation for biologics (adalimumab, certolizumab pegol, secukinumab, and ixekizumab) in 146 prescriptions (of which, 109 prescriptions were as naive) at our hospital since March 2010.

Results

Throughout the entire course of the study, the 10-year retention rates were approximately 70% for adalimumab, 50% for ixekizumab, and 40% for secukinumab. When evaluating retention rates in the biologic-naïve subgroups, the 10-year retention rates were all approximately 70%. Regarding certolizumab pegol, the 3-year retention rate was approximately 75%. For adalimumab, a higher degree of arthritis at the initiation of treatment was found to correlate with an increased likelihood of secondary inefficacy. The main reason for discontinuation was secondary inefficacy, except for ixekizumab.

Conclusions

Each biologic exhibited a favourable long-term retention rate. The main reason for discontinuation was secondary inefficacy. Regarding adalimumab, secondary inefficacy was linked to the extent of arthritis upon treatment initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticInterleukin-17Antibodies, Monoclonal, HumanizedAntirheumatic AgentsHumansMaleFemaleMiddle AgedAdultAdalimumabTumor Necrosis Factor-alphaCertolizumab PegolAgedBiological ProductsTreatment Outcome

Stichwörter der Autor:innen

Biologicsdropoutpsoriatic arthritisretention ratesecondary inefficacy

Substanzen

Interleukin-17Antibodies, Monoclonal, HumanizedixekizumabAntirheumatic AgentssecukinumabAdalimumabTumor Necrosis Factor-alphaCertolizumab PegolBiological Products

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Nippon Life Hospital, Osaka, Japan.
  • Department of Rehabilitation, Nippon Life Hospital, Osaka, Japan.
  • Department of Dermatology, Nippon Life Hospital, Osaka, Japan.
  • Department of Respiratory Medicine and Clinical Immunology, Nippon Life Hospital, Osaka, Japan.

ORCID-Profile: Kenji Takami

Zitieren

APA

Takami, K., Tsuji, S., Sato, S., Akaji, K., Yamashita, C., Hiroumi, S., Konaka, H., Hayashi, M., & Higashiyama, M. (2024). Long-term retention rates of anti-tumour necrosis factor and anti-interleukin-17 antibodies for patients with psoriatic arthritis. Modern Rheumatology. https://doi.org/10.1093/mr/road111

Vancouver

Takami K, Tsuji S, Sato S, Akaji K, Yamashita C, Hiroumi S, et al. Long-term retention rates of anti-tumour necrosis factor and anti-interleukin-17 antibodies for patients with psoriatic arthritis. Modern Rheumatology. 2024. doi:10.1093/mr/road111

BibTeX
@article{Takami2024,
  author = {Takami, Kenji and Tsuji, Shigeyoshi and Sato, Sachina and Akaji, Kazuya and Yamashita, Chigusa and Hiroumi, Shiori and Konaka, Hachiro and Hayashi, Misa and Higashiyama, Mari},
  title = {Long-term retention rates of anti-tumour necrosis factor and anti-interleukin-17 antibodies for patients with psoriatic arthritis},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/road111}
}
Kostenlos starten →